GI Dynamics Announces an Update to the Worldwide Registry Data for 1,022 Patients Recently Published in Diabetes Care, the Journal of the American Diabetes Association
Data demonstrate favorable safety and efficacy profile for the duodenal jejunal bypass liner (DJBL) technology BOSTON — April 4, 2023 — GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is...GI Dynamics Announces First Patient Enrolled in the I-STEP Clinical Study of EndoBarrier in India
Trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity BOSTON & HYDERABAD, India–(BUSINESS WIRE)– GI Dynamics Inc., a medical device company that is developing the EndoBarrier® System for patients...Duodenal-jejunal bypass liner for treatment of T2DM and obesity: 4-year outcomes in the first National Health Service (NHS) EndoBarrier service
Our data demonstrate that EndoBarrier is highly effective in people with refractory diabesity, with maintenance of significant improvement three years after removal in 77% of cases.Impact of duodenal-jejunal bypass liner (DJBL) on NAFLD in patients with obesity and type 2 diabetes mellitus
Significant effects of DJBL treatment on NAFLD fibrosis and APRI score further suggests protective effects of DJBL on liver-related morbidity and mortality in patients with obesity and T2DM.GI Dynamics Announces the Presentation of Updated Data Sets at the 2022 Meeting of the American Diabetes Association
Data demonstrate favorable safety and efficacy profile for the duodenal jejunal bypass liner (DJBL) technology BOSTON — July 13, 2022 — GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is...GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is...GI Dynamics Announces Approval of the I-STEP Clinical Study in India
Trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity BOSTON & HYDERABAD, India–(BUSINESS WIRE)– GI Dynamics Inc., a medical device company that is developing the EndoBarrier® System for patients...GI Dynamics Appoints New Chief Executive Officer and Board of Directors
BOSTON — November 5, 2020 — GI Dynamics® Inc. (“GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, has appointed Joseph Virgilio as president and chief executive officer of GI...GI Dynamics Completes Initial Closing of a $10 Million Series A Preferred Stock Financing from Crystal Amber
BOSTON — September 10, 2020 — GI Dynamics® Inc. (‘GI Dynamics” or the “Company”), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the initial closing of its private placement offering of...Videos
How EndoBarrier Works
EndoBarrier: Non-surgical Treatment for Patients with Type 2 Diabetes and …
Maintenance of Efficacy after EndoBarrier
UK First NHS EndoBarrier Service – Dr. Bob Ryder June …
BBC News Item
EndoBarrier treatment for diabetes & obesity following 1 year results …
